Benefits
Cognitive performance + cerebrovascular function in postmenopausal women (RESHAW)
RESHAW (Resveratrol Supporting Healthy Aging in Women) clinical study — published in Nutrients April 2020. 129 postmenopausal women aged 45-85 randomized to 75 mg trans-resveratrol (Veri-te™) twice daily or placebo for 12 months. RESULTS: Daily Veri-te resveratrol IMPROVED COGNITIVE PERFORMANCE and REDUCED DECLINE in CEREBROVASCULAR RESPONSIVENESS (CVR). Largest, longest-running resveratrol cognition study at the time. Conducted at University of Newcastle, Australia. Foundational pivotal evidence for postmenopausal cognitive aging.
Bone mineral density improvements (RESHAW bone arm)
RESHAW Trial — 125 postmenopausal women, 24-month design (12-month crossover), peer-reviewed publication. Veri-te resveratrol IMPROVED BONE DENSITY in LUMBAR SPINE and FEMORAL NECK of postmenopausal women. 7.2% RELATIVE REDUCTION of plasma C-terminal telopeptide type-1 collagen (marker of bone resorption). Participants with greater bone resorption at baseline showed greater reduction with resveratrol — SUBGROUP-DEPENDENT EFFICACY pattern. Important osteoporosis-prevention application.
Bone mineral density obese men (Ornstrup 2014 PMID 25494663)
Ornstrup 2014 (PMID 25494663, J Clin Endocrinol Metab) — randomized placebo-controlled trial. Obese men. RESVERATROL INCREASES BONE MINERAL DENSITY and BONE ALKALINE PHOSPHATASE. Foundational bone health evidence in male obese population. Different population than RESHAW but consistent bone benefits direction. Veri-te™ specifically used in this trial.
Pain perception + menopausal symptoms + quality of life (RESHAW final publication)
RESHAW Final Publication (Journal of The North American Menopause Society) — 'Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women.' 24-month Veri-te resveratrol supplementation final publication. Multi-domain benefits in postmenopausal women: chronic pain reduction, menopausal symptoms reduction, overall well-being improvement. Important quality-of-life evidence beyond surrogate biomarkers.
Blood pressure improvements (Wong et al.)
Wong et al. study in 19 overweight/obese men and postmenopausal women with untreated high blood pressure. Three doses of resveratrol at weekly intervals vs placebo. RESULTS: SIGNIFICANT IMPROVEMENTS in blood pressure markers vs placebo. Foundational cardiovascular evidence supporting Veri-te applications.
Pharmaceutical-grade yeast fermentation purity advantage
Veri-te™ is YEAST-FERMENTED pharmaceutical-grade trans-resveratrol — NOT extracted from Japanese knotweed (Polygonum cuspidatum). Distinguishing manufacturing advantages: (1) HIGHER PURITY (>98% trans-resveratrol vs typical knotweed extracts containing emodin and other compounds), (2) NO emodin contamination (laxative anthraquinone present in knotweed extracts), (3) sustainable production not dependent on wild knotweed harvesting, (4) Cincinnati University and other pharma-grade research applications, (5) consistent batch-to-batch potency.
Endothelial function in postmenopausal women
Howe research group documented improvements in endothelial tissue maintenance in postmenopausal women with Veri-te resveratrol — relevant to cardiovascular event risk. Mechanism: resveratrol effects on NO production + SIRT1 activation + endothelial cell function. Important cardiovascular evidence in high-risk postmenopausal population.
Mechanism of action
SIRT1 activation (longevity pathway)
Resveratrol activates SIRT1 (sirtuin 1) — NAD+-dependent deacetylase central to longevity, mitochondrial biogenesis, glucose/lipid metabolism, and cellular stress resistance. Foundation longevity mechanism.
AMPK activation
Activates AMP-activated protein kinase (AMPK) — energy-sensing pathway connecting metabolism, autophagy, and longevity. Mechanism for metabolic and cardiovascular benefits.
Endothelial NO production enhancement
Improves endothelial nitric oxide synthase activity → enhanced NO production → vasodilation + cerebrovascular function. Mechanism for cardiovascular AND cognitive (cerebrovascular) effects in RESHAW.
Estrogen receptor modulation
Mild estrogen receptor binding (phytoestrogen). Mechanism for menopausal symptom benefits + bone density support. Selective estrogen receptor modulator-like activity at typical doses.
Bone metabolism modulation
Reduces bone resorption markers (C-terminal telopeptide type-1 collagen 7.2% reduction in RESHAW). Increases bone alkaline phosphatase (Poulsen 2014, Ornstrup 2014). Supports bone formation. Mechanism for bone density improvements.
Anti-inflammatory NF-κB pathway suppression
Suppresses NF-κB activation and pro-inflammatory cytokines. Mechanism for chronic inflammation reduction relevant to cardiovascular, cognitive, and bone aging.
Antioxidant + mitochondrial biogenesis
Direct antioxidant + induces mitochondrial biogenesis via PGC-1α. Mechanism for cellular energetics and longevity-relevant pathways.
Clinical trials
Double-blind randomized placebo-controlled trial (Howe P, Wong R, Thaung Zaw JJ et al. 2020, Nutrients). Resveratrol Supporting Healthy Ageing in Women.
129 postmenopausal women aged 45-85 years. Two capsules of 75 mg Evolva's Veri-te resveratrol daily (150 mg/day) vs matching placebo for 12 months. Cognitive performance + cerebral blood flow + cerebrovascular responsiveness (CVR) + cardiometabolic markers measured. University of Newcastle, Australia. ANZCTR ID 370696.
Daily Veri-te resveratrol supplementation IMPROVED COGNITIVE PERFORMANCE and REDUCED DECLINE in CEREBROVASCULAR RESPONSIVENESS (CVR). LARGEST, LONGEST-RUNNING study of its kind with resveratrol at the time. Confirms previous observations that REGULAR LOW-DOSE resveratrol can SUSTAIN CEREBROVASCULAR FUNCTION. Foundational cognitive aging evidence in postmenopausal women. INDUSTRY-SPONSORED (Evolva) — important context.
Randomized placebo-controlled crossover trial (RESHAW Trial Bone Mineral Density Publication, peer-reviewed). University of Newcastle Clinical Nutrition Research Centre, Australia.
125 postmenopausal women. Two capsules of 75 mg Veri-te resveratrol daily vs matching placebo for 12 months, followed by ALTERNATE TREATMENT for 12 months (24-month total crossover design). Bone density in critical regions + biomarkers of bone metabolism + body composition measured.
Veri-te resveratrol IMPROVED BONE DENSITY in LUMBAR SPINE and FEMORAL NECK of postmenopausal women. 7.2% RELATIVE REDUCTION of plasma C-terminal telopeptide type-1 collagen (marker of bone resorption). SUBGROUP-DEPENDENT: participants with greater bone resorption at baseline showed greater reduction with resveratrol — important responder population insight. Foundational bone health evidence.
Randomized placebo-controlled trial (Ornstrup MJ, Harslof T, Kjaer TN, Langdahl BL, Pedersen SB 2014, J Clin Endocrinol Metab, doi:10.1210/jc.2014-2799, PMID 25494663).
Obese men. Resveratrol vs placebo with bone mineral density assessment.
RESVERATROL INCREASES BONE MINERAL DENSITY and BONE ALKALINE PHOSPHATASE in obese men. Foundational bone health evidence in male obese population complementing RESHAW postmenopausal women evidence. DIFFERENT POPULATION but consistent bone benefits direction. Veri-te™ specifically used in this trial.
About this ingredient
Veri-te™ Resveratrol is a BRANDED YEAST-FERMENTED PHARMACEUTICAL-GRADE trans-RESVERATROL manufactured by EVOLVA HOLDING (Swiss biotech). DISTINGUISHING FEATURE: produced via PROPRIETARY YEAST FERMENTATION rather than extraction from Japanese knotweed (Polygonum cuspidatum) — the typical commercial source. Manufacturing advantages: (1) >98% trans-resveratrol PURITY (vs variable knotweed extracts), (2) NO EMODIN contamination (laxative anthraquinone present in knotweed), (3) sustainable production independent of wild knotweed harvesting, (4) consistent batch-to-batch potency suitable for pharmaceutical research applications (Cincinnati University etc.), (5) GMP-compliant manufacturing. Launched 2017 as 'new generation resveratrol made by an innovative process.' Now major resveratrol market player. PIVOTAL CLINICAL EVIDENCE: RESHAW (Resveratrol Supporting Healthy Ageing in Women) Trial — University of Newcastle, Australia (Howe P, Wong R, Thaung Zaw JJ et al.). 12-MONTH PHASE 1 in 129 postmenopausal women aged 45-85 at 75 mg twice daily (150 mg/day): IMPROVED COGNITIVE PERFORMANCE + reduced decline in CEREBROVASCULAR RESPONSIVENESS (Nutrients 2020 publication). 24-MONTH CROSSOVER BONE ARM (n=125): IMPROVED BONE DENSITY in lumbar spine + femoral neck + 7.2% reduction in plasma CTX-I bone resorption marker (subgroup-dependent for those with higher baseline resorption). FINAL PUBLICATION (J North American Menopause Society): improved pain perception + menopausal symptoms + overall well-being. ORNSTRUP 2014 PMID 25494663 (J Clin Endocrinol Metab) bone mineral density trial in obese men. POULSEN 2014 short-term bone-specific alkaline phosphatase trial. WONG et al. blood pressure trial in 19 overweight/obese hypertensive subjects. ONGOING TRIALS: U Newcastle 24-month n=160 cardiometabolic/brain/bone; UC San Diego/Poznan PCOS trial (simvastatin + 500 mg resveratrol for 6 months in 60 women); Max Planck Leipzig cognition trial (resveratrol + quercetin in 60 subjects >60 years for 6 months).
MECHANISMS: SIRT1 activation (longevity pathway central mechanism); AMPK activation (energy sensing); endothelial NO production enhancement; estrogen receptor modulation (mild phytoestrogenic — explains menopausal benefits); bone metabolism modulation (reduces bone resorption markers, increases bone alkaline phosphatase); NF-κB anti-inflammatory pathway suppression; antioxidant + mitochondrial biogenesis via PGC-1α. EVIDENCE: 3/5 reflects: (1) RESHAW PIVOTAL multi-arm 12-24 month RCT in postmenopausal women with COGNITIVE + BONE + QUALITY-OF-LIFE benefits, (2) ORNSTRUP 2014 PMID 25494663 bone mineral density obese men trial, (3) MULTIPLE ongoing pharmaceutical-grade research applications, (4) WELL-CHARACTERIZED multi-target SIRT1/AMPK/NO mechanisms, (5) SUBGROUP-DEPENDENT efficacy pattern (higher-resorption baseline benefits more), (6) PHARMACEUTICAL-GRADE yeast-fermentation purity advantage over typical knotweed extracts, (7) 24-month longest-available resveratrol RCT data, (8) industry-sponsored evidence (Evolva) — important context but methodology rigorous, (9) higher-evidence than typical resveratrol supplements due to purity + dedicated RCTs. SAFETY: Excellent — 24-month RESHAW trial supports long-term safety. Best positioned as: (a) POSTMENOPAUSAL WOMEN cognitive aging adjunct (RESHAW PIVOTAL evidence), (b) POSTMENOPAUSAL BONE DENSITY adjunct (RESHAW bone arm + Ornstrup obese men evidence), (c) MENOPAUSAL SYMPTOMS + QUALITY-OF-LIFE adjunct (RESHAW final publication), (d) CARDIOVASCULAR adjunct (Wong et al. BP evidence), (e) LONGEVITY/HEALTHSPAN adjunct via SIRT1 mechanism, (f) PHARMACEUTICAL-GRADE alternative to knotweed-derived resveratrol (no emodin), (g) DAILY long-term use acceptable based on 24-month safety data, (h) PREGNANCY: AVOID (theoretical estrogenic effects). Honest framing: Veri-te™ has more rigorous evidence than typical resveratrol supplements — RESHAW Trial provides the LONGEST RUNNING RESVERATROL STUDY in postmenopausal women with multi-domain positive outcomes (cognitive + bone + quality-of-life). The yeast-fermentation advantage (no emodin contamination, pharmaceutical-grade purity) is a genuine quality distinction. Subgroup-dependent efficacy in bone arm important nuance. Industry sponsorship (Evolva) warrants caveat but methodology consistently rigorous. Reasonable postmenopausal cognitive aging + bone health adjunct based on evidence.